

SUBB2M US PATENT GRANT AND PROGRAM UPDATE

- US Patent No 11,371,033 granted covering the SubB2M technology
- Provides IP protection in the USA for SubB2M-based diagnostics
- SubB2M assay successfully replicated by ResearchDx, now undergoing optimisation and validation

Melbourne, Australia, 1 July 2022: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) announces that United States of America Patent No 11,371,033 entitled ‘Subtilase cytotoxin B subunit mutant’ was issued by the United States Patent and Trademark Office to Griffith University and the University of Adelaide. The patent covers the SubB2M technology and INOVIQ Ltd holds the exclusive worldwide rights to the SubB2M intellectual property for diagnostic applications.

US patent 11,371,033 is due to expire on 9 July 2038 and claims modified SubB proteins capable of binding N-glycolylneuraminic acid (Neu5Gc) and variants and fragments thereof, such as SubB2M. This US patent grant follows the recent grant of an Australian patent for the SubB2M technology (ASX: 3 May 2022).

CEO Dr Leearne Hinch said: *“This patent enforces intellectual property protection in the USA for INOVIQ’s SubB2M-based diagnostics pipeline for the monitoring of breast and ovarian cancers. The granting of this US patent is an important achievement for the Company as the US is the first market where the SubB2M tests are being commercialised as Laboratory Developed Tests.*

INOVIQ has been making solid progress on the SubB2M program and we’re pleased to report that the performance of the SubB2M-CA15.3 assay for detection of breast cancer has been successfully replicated by ResearchDx. The assay is now undergoing optimisation and validation before advancing to clinical testing for breast cancer monitoring. This is an exciting step forward for the SubB2M diagnostics program.”

SubB2M technology and tests

The SubB2M technology is based on an engineered protein that specifically detects the pan-cancer biomarker Neu5Gc that is found in multiple human cancers including breast, ovarian, prostate and others.

INOVIQ’s SubB2M diagnostics pipeline includes SubB2M-based immunoassays for monitoring of breast and ovarian cancers, and a SubB2M-based surface plasmon resonance (SPR) test for the detection of Neu5Gc levels in a general health panel.

SubB2M recent milestones and development path

In addition to today’s update, INOVIQ has recently achieved several key milestones in advancing the commercialisation of its SubB2M tests. These include the signing of a Master Services Agreement with US-based contract diagnostics organisation ResearchDx for the development and validation of its SubB2M-based tests in the USA (ASX: 5 April 2022), and a Master Manufacturing Agreement with MP Biomedicals Asia Pacific Pte Ltd for contract manufacture of the SubB2M protein to cGMP standard (ASX: 2 May 2022).

The SubB2M tests are now undergoing optimisation and validation (using the GMP-grade SubB2M) at ResearchDx before advancing to clinical testing for breast cancer monitoring.

Authorised by the Company Secretary, Tony Di Pietro.

– ENDS –

COMPANY CONTACTS

Dr Leearne Hinch
Chief Executive Officer
E: lhinch@inoviq.com
M: +61 400 414 416

Dr Geoff Cumming
Non-Executive Chairman
E: geoff.cumming@inoviq.com
M: +61 417 203 021

Jane Lowe
IR Department
E: jane.lowe@irdepartment.com.au
M: +61 411 117 774

ABOUT INOVIQ

INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising innovative diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases.

The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see www.inoviq.com.

FORWARDING LOOKING STATEMENTS

This announcement contains certain ‘forward-looking statements’ within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as ‘may’, ‘should’, ‘expect’, ‘anticipate’, ‘estimate’, ‘scheduled’ or ‘continue’ or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.